Wednesday, July 26 2:45 – 3:45 p.m. Exhibit Hall Theater 1 Supported by Thermo Fisher Scientific
Learn from our two speakers about the new biomarkers PlGF, sFlt-1, and CgA for management of preeclampsia and neuroendocrine tumors. Preeclampsia is a life-threatening pregnancy complication affecting 8% of the pregnant women in the United States. PlGF and sFlt-1 can help to identify hospitalized women who will progress to a severe form of preeclampsia, thus improving clinical management of this condition. Chromogranin A (CgA) is a tumor marker recognized as gold standard in grade 1/2 neuroendocrine tumors. Although widely known, only LDTs – usually manual – are available in the United States. Currently, FDA 510K is pending for B·R·A·H·M·S CgAII KRYPTOR, the only fully automated CgA assay.
Kai Staeding Product Manager, Thermo Fisher Scientific
Anders Berg Associate Professor, Pathology, Bioscience Associate Director, Clinical Chemistry Cedars Sinai
Be the first to get all the latest news.